Initiator Pharma A/S

Initiator Pharma A/S FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Initiator Pharma A/S (INIT.ST) as of Nov 3, 2026 is 259.62 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 93,411.69 % — a change of -99.72% (lower).

FCF Conversion

259.62 %

YoY

-99.72%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Initiator Pharma A/S is 2025 259.62 % . FCF Conversion Rate (FCF/EBITDA) of Initiator Pharma A/S was 2024 93,411.69 % . It decreases by -99.72% lower compared to the previous year.

The Initiator Pharma A/S FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
131.89 DKK
Jan 1, 2019
103.20 DKK
Jan 1, 2020
92.72 DKK
Jan 1, 2021
161.87 DKK
Jan 1, 2022
85.04 DKK
Jan 1, 2023
77,152.10 DKK
Jan 1, 2024
93,411.69 DKK
Jan 1, 2025
259.62 DKK
The Initiator Pharma A/S FCF Conversion history
YEARFCF ConversionYoY
259.62 %-99.72%
93,411.69 %+21.07%
77,152.10 %+90,627.62%
85.04 %-47.47%
161.87 %+74.58%
92.72 %-10.15%
103.20 %-21.75%
131.89 %+42.99%
92.24 %+131.77%
39.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Initiator Pharma A/S Stock analysis

What does Initiator Pharma A/S do? Initiator Pharma A/S is a clinical-stage biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. The company develops novel therapeutics targeting monoamine reuptake transporters for central nervous system disorders, with a focus on erectile dysfunction treatments. Initiator Pharma A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Initiator Pharma A/S stock

FCF Conversion Rate (FCF/EBITDA) of Initiator Pharma A/S is 259.62 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Initiator Pharma A/S changed from 93,411.69 % to 259.62 %, representing a -99.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Initiator Pharma A/S since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Initiator Pharma A/S with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Initiator Pharma A/S

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Initiator Pharma A/S